TG Therapeutics, Inc. (TGTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 2 GANSEVOORT STREET, 9TH FLOOR
NEW YORK, NY 10014
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:174,100350,300605,400140,40068,80684,717
Cash and cash equivalents102,304298,887553,439112,63741,95856,718
Short-term investments59,37415,87651,98727,79826,84827,999
Other undisclosed cash, cash equivalents, and short-term investments12,42235,537(26)(35)  
Receivables 1,389  95108
Inventory, net of allowances, customer advances and progress billings      
Inventory      
Other current assets2,3592,8841,083611439437
Other undisclosed current assets(8,185)(23,608)5,2578,1409,6918,055
Total current assets:168,274330,965611,740149,15179,03193,317
Noncurrent Assets
Operating lease, right-of-use asset8,8888,6299,3129,402
Property, plant and equipment307600481282251248
Long-term investments and receivables 12,40435,533    
Long-term investments 12,40435,533    
Intangible assets, net (including goodwill)799799799799799799
Goodwill799799799799799799
Regulated entity, other noncurrent assets   1,0802,005  
Restricted cash and investments1,2731,2641,259 1,241587
Other undisclosed noncurrent assets1,6271,8399711,3752,2942,429
Total noncurrent assets:25,29848,66413,90213,8634,5854,064
TOTAL ASSETS:193,572379,629625,642163,01483,61697,382
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:42,01951,29437,01430,04136,37725,877
Other undisclosed accounts payable and accrued liabilities42,01951,29437,01430,04136,37725,877
Deferred revenue    
Debt  97523,8481,61667128
Deferred compensation liability8,43210,1668,4563,7982,2581,800
Deferred revenue and credits152
Other liabilities1,1691,51218,23648,994  
Other undisclosed current liabilities1,5811,437  152 
Total current liabilities:53,20165,38487,55484,44938,85427,957
Noncurrent Liabilities
Long-term debt and lease obligation71,13576,63518,12839,188  
Long-term debt, excluding current maturities71,13566,7887,71628,970  
Liabilities, other than long-term debt10,64945761076219,8122,431
Deferred revenue and credits2,431
Deferred revenue305457610762
Deferred rent credit     1,462
Other liabilities     18,350 
Operating lease, liability10,3449,84710,41210,218
Other undisclosed noncurrent liabilities     914 
Total noncurrent liabilities:81,78477,09218,73839,95020,7262,431
Total liabilities:134,985142,476106,292124,39959,58030,388
Equity
Equity, attributable to parent58,821237,153519,35038,61524,03666,993
Common stock1461431411098473
Treasury stock, value (234)(234)(234)(234)(234)
Additional paid in capital1,585,7081,565,9421,500,040739,956552,531422,017
Accumulated deficit(1,527,033)(1,328,698)(980,597)(701,216)(528,345)(354,863)
Other undisclosed equity (234)     
Total equity:58,587237,153519,35038,61524,03666,993
TOTAL LIABILITIES AND EQUITY:193,572379,629625,642163,01483,61697,382

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues2,7856,689152152152152
Amortization of lease incentives(216)(182) 
Revenue, net152
Other income4,6952,3075421,47161 
Cost of revenue
(Cost of Goods and Services Sold)
      
Gross profit:2,7856,689152152152152
Operating expenses(195,624)(351,459)(273,746)(169,207)(174,552)(118,864)
Operating loss:(192,839)(344,770)(273,594)(169,055)(174,400)(118,712)
Nonoperating income (expense)(5,496)(3,331)(5,787)(3,816)918236
Investment income, nonoperating331(517)30257119(61)
Other nonoperating income      
Interest and debt expense(10,191)(5,638)(6,329)(5,287)  
Other undisclosed income from continuing operations before equity method investments, income taxes   6,3295,287  
Loss from continuing operations before equity method investments, income taxes:(208,526)(353,739)(279,381)(172,871)(173,482)(118,476)
Other undisclosed income from continuing operations before income taxes10,1915,638    
Loss from continuing operations:(198,335)(348,101)(279,381)(172,871)(173,482)(118,476)
Loss before gain (loss) on sale of properties:(348,101)(279,381)(172,871)(173,482)(118,476)
Other undisclosed net loss      
Net loss:(198,335)(348,101)(279,381)(172,871)(173,482)(118,476)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(198,335)(348,101)(279,381)(172,871)(173,482)(118,476)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(198,335)(348,101)(279,381)(172,871)(173,482)(118,476)
Comprehensive loss, net of tax, attributable to parent:(198,335)(348,101)(279,381)(172,871)(173,482)(118,476)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: